Lead Product(s): ISD-017
Therapeutic Area: Immunology Product Name: ISD-017
Highest Development Status: Preclinical Product Type: Peptide
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 23, 2020
ISD and Biogen will work together to develop ISD's lead compound, ISD 017, which is being developed to treat severe lupus - systemic lupus erythematosus (SLE).